Citation Impact
Citing Papers
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies
2008 Standout
Evidence for a functional RNA element in the hepatitis C virus core gene
2007 StandoutNobel
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial
2005 Standout
The global burden of hepatitis C
2009
PHOENIX
2011
Hepatitis C virus: Epidemiology and transmission
1997
Why gold nanoparticles are more precious than pretty gold: Noble metal surface plasmon resonance and its enhancement of the radiative and nonradiative properties of nanocrystals of different shapes
2005 Standout
Hepatitis B Virus Infection — Natural History and Clinical Consequences
2004 Standout
Natural history of hepatitis B
2003
Peginterferon alfa‐2a for hepatitis C after liver transplantation
2005
Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease
2003
A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C
2007
The impact of disease recurrence on graft survival following liver transplantation: a single centre experience
2008
Real-time PCR in virology
2002
Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation
2009
Unravelling hepatitis C virus replication from genome to function
2005 StandoutNatureNobel
Hepatitis B and Hepatitis C Viruses in Liver Transplantation
2004
Hepatitis B viral genotypes: Clinical relevance and molecular characteristics
2002
Hepatitis B: Reflections on the current approach to antiviral therapy
2008
Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures
2010 StandoutNobel
Molecular Diagnostics of Hepatitis C Virus Infection
2007
Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C
2002
Report of the Monothematic EASL Conference on Liver Transplantation for Viral Hepatitis
2006
Pegylated Interferon and Ribavirin for the Recurrence of Chronic Hepatitis C Genotype 1 in Transplant Patients
2005
Hepatitis B virus infection
2009 Standout
Histopathologic Efficacy of Ribavirin Monotherapy in Kidney Allograft Recipients with Chronic Hepatitis C
2004
Chronic hepatitis B
2001
Natural history of chronic HBV infection: A cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project)
2005
Advances in Surface-Enhanced Fluorescence
2004
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
2004 Standout
Hepatitis B e antigen-negative chronic hepatitis B
2001
Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C
2006
Hepatitis B virus genotypes in the United States: results of a nationwide study
2003
Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naïve and non-responder patients on a stable immunosuppressive regimen
2005
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
Long‐term follow‐up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver‐related complications
2006
Chronic hepatitis C virus infection in renal transplant: treatment and outcome
2006
Management of Hepatocellular Carcinoma *
2005 Standout
Prevention and treatment of hepatitis C virus recurrence after liver transplantation
2004
Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses
2008
Treating viral hepatitis C: efficacy, side effects, and complications
2006
A Human Monoclonal Antibody Targeting Scavenger Receptor Class B Type I Precludes Hepatitis C Virus Infection and Viral Spread In Vitro and In Vivo
2011 StandoutNobel
Retransplantation in patients with hepatitis C recurrence after liver transplantation
2010
Hepatitis C and Liver Transplantation: Enhancing Outcomes and Should Patients Be Retransplanted
2008
Combined treatment with pegylated interferon (α-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation
2005
Cell culture–produced hepatitis C virus does not infect peripheral blood mononuclear cells
2008 StandoutNobel
Priming of hepatitis C virus-specific cytotoxic t lymphocytes in mice following portal vein injection of a liver-specific plasmid DNA
2000 StandoutNobel
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
2006 Standout
Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C
2002
Chronic hepatitis B
2007 Standout
ULTRALOW-DOSE ALPHA-INTERFERON PLUS RIBAVIRIN FOR THE TREATMENT OF ACTIVE HEPATITIS C IN RENAL TRANSPLANT RECIPIENTS
2004
Liver transplantation and hepatitis C
2011
The ins and outs of hepatitis C virus entry and assembly
2013 StandoutNobel
The natural history of chronic hepatitis B virus infection #
2009
Chronic hepatitis B: Update 2009 #
2009 Standout
DNA hybridization assays using metal-enhanced fluorescence
2003
Hepatitis C virus antigen in hepatocytes: Immunomorphologic detection and identification
1992 StandoutNobel
Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells
2006 StandoutNobel
Hepatitis C and renal disease: an update
2003
Integrated Nanoparticle–Biomolecule Hybrid Systems: Synthesis, Properties, and Applications
2004 Standout
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
2009 StandoutNature
Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation
2010
A short course of pegylated interferon‐αin acute HCV hepatitis
2006
Occult hepatitis B virus infection
2006
Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia
2006
Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence
2007
Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia
2008
Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients
2002
Occult hepatitis B
2002
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Prevalence of Hbv Precore/Core Promoter Variants in the United States
2003
A Hepatitis C Virus (HCV) Vaccine Comprising Envelope Glycoproteins gpE1/gpE2 Derived from a Single Isolate Elicits Broad Cross-Genotype Neutralizing Antibodies in Humans
2013 StandoutNobel
Treatment of Patients with Recurrent Hepatitis C after Liver Transplantation with Peginterferon Alfa-2B Plus Ribavirin
2006
Infection in Solid-Organ Transplant Recipients
2007 Standout
Antiretroviral Treatment of Adult HIV Infection
2012 Standout
Efficacy of Antiviral Therapy on Hepatitis C Recurrence After Liver Transplantation: A Randomized Controlled Study
2007
The way forward in HCV treatment — finding the right path
2007 StandoutNobel
Hepatitis C Recurrence After Liver Transplantation: Viral and Histologic Response to Full-Dose Peg-Interferon and Ribavirin
2006
Antigenic relevance of F protein in chronic hepatitis C virus infection
2004
Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection
2002
Replication of hepatitis C virus
2007 StandoutNobel
Real-time PCR in the microbiology laboratory
2004
Sustained response after a 2‐year course of lamivudine treatment of hepatitis B e antigen‐negative chronic hepatitis B
2004
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles
2003 StandoutNobel
Antigenic relevance of F protein in chronic hepatitis C virus infection
2004
Hepatitis B Virus Biology
2000
Memory T-Cell-Mediated Immune Responses Specific to an Alternative Core Protein in Hepatitis C Virus Infection
2004
Subcellular Localization, Stability, and trans -Cleavage Competence of the Hepatitis C Virus NS3-NS4A Complex Expressed in Tetracycline-Regulated Cell Lines
2000 StandoutNobel
Broadly Neutralizing Immune Responses against Hepatitis C Virus Induced by Vectored Measles Viruses and a Recombinant Envelope Protein Booster
2012 StandoutNobel
Preferential association of Hepatitis C virus with apolipoprotein B48-containing lipoproteins
2006
The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments
2009 Standout
Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation
2004
High-Avidity Monoclonal Antibodies against the Human Scavenger Class B Type I Receptor Efficiently Block Hepatitis C Virus Infection in the Presence of High-Density Lipoprotein
2007 StandoutNobel
Treatment of Hepatitis C Virus Infection (HCV) After Renal Transplantation: Implications for HCV-Positive Dialysis Patients Awaiting a Kidney Transplant
2006
Eradication of Hepatitis C Virus in Patients Successfully Treated for Chronic Hepatitis C
2008
Studying Hepatitis C Virus: Making the Best of a Bad Virus
2007 StandoutNobel
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
2007 Standout
Experimental non‐A, non‐B hepatitis in chimpanzees: Light, electron and immune microscopical observations
1983
Nanostructured Plasmonic Sensors
2008 Standout
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
Fibrosis — A Common Pathway to Organ Injury and Failure
2015 Standout
Carbon Nanomaterials for Biological Imaging and Nanomedicinal Therapy
2015 Standout
Prevention of hepatitis C virus infection using a broad cross‐neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate
2015 StandoutNobel
Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins
1998 StandoutNobel
Expression of hepatitis C virus proteins in epithelial intestinal cells in vivo
2004
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine
2018 StandoutNobel
Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents
2014 StandoutNobel
Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles
2002
Detection of non-A, non-B hepatitis antigen by immunocytochemical staining.
1984
Hepatitis C Virus Glycoproteins Interact with DC-SIGN and DC-SIGNR
2003 StandoutNobel
Mutations in Hepatitis C Virus E2 Located outside the CD81 Binding Sites Lead to Escape from Broadly Neutralizing Antibodies but Compromise Virus Infectivity
2009 StandoutNobel
Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells
2013 StandoutNobel
Different Requirements for Scavenger Receptor Class B Type I in Hepatitis C Virus Cell-Free versus Cell-to-Cell Transmission
2013 StandoutNobel
Developments in liver transplantation
2004
Detection by immunofluorescence of an antigen‐antibody system in patients with acute and chronic non‐A, non‐B hepatitis
1981
Role of Scavenger Receptor Class B Type I in Hepatitis C Virus Entry: Kinetics and Molecular Determinants
2009 StandoutNobel
Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection
2002
Works of Philippe Chevallier being referenced
Long-Term Antiviral Therapy for Recurrent Hepatitis C After Liver Transplantation in Nonresponders: Biochemical, Virological, and Histological Impact
2008
Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination
2004
High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology
2001
Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients
1997
Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity
2000
Combined Lamivudine and Hepatitis B Immunoglobulin for the Prevention of Hepatitis B Recurrence after Liver Transplantation: Long‐Term Results
2003
Quantitation of HCV RNA using real-time PCR and fluorimetry
2001
Survival in HIV‐infected patients is associated with hepatitis C virus infection and injecting drug use since the use of highly active antiretroviral therapy in the Lyon observational database
2004
Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure
2004
Occult HBV infection may represent a major risk factor of non‐response to antiviral therapy of chronic hepatitis C
2007
Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence
2003
Effectiveness of early a-interferon therapy for hepatitis C virus infection recurrence after liver transplantation
1996
Early and frequent detection of HBxAg and/or anti-HBx in hepatitis B virus infection
1990
Comparison of HCV RNA assays for the detection and quantification of hepatitis C virus RNA levels in serum of patients with chronic hepatitis C treated with interferon
1997
Detection by immunofluorescence of a new “core‐like” Ag/Ab system in liver and serum of patients with NANB hepatitis
1981
Co-infection by hepatitis B virus and hepatitis C virus in renal transplantation: morbidity and mortality in 1098 patients
1995
[Early treatment of acute hepatitis C with interferon alpha-2b or interferon alpha-2b plus ribavirin: study of sixteen patients].
2003
Identification and detection of long incubation non-A, non-B hepatitis virus and associated antigens or antibodies
1980